Top 10 Companies in the Amino Acids for Peptide Drug Synthesis Market (2026): Market Leaders Powering Global Therapeutics

MARKET INSIGHTS

Global amino acids for peptide drug synthesis market was valued at USD 414 million in 2024 and is projected to reach USD 727 million by 2032, growing at a CAGR of 9.0% during the forecast period.

Amino acids serve as fundamental building blocks in peptide drug synthesis, forming biologically active compounds through peptide bond formation. These pharmaceutical-grade amino acids enable precise construction of therapeutic peptides that target specific disease mechanisms with high specificity. The market encompasses essential amino acids like lysine, methionine, threonine, and tryptophan, which influence peptide stability, bioavailability, and target binding affinity.

Market growth is driven by increasing R&D investment in peptide therapeutics, which accounted for over 20% of new drug approvals in 2023. While SPPS (Solid-Phase Peptide Synthesis) dominates current manufacturing, emerging technologies like continuous flow synthesis are gaining traction. Key players including Bachem and Merck are expanding production capacities to meet demand, with the lysine segment expected to grow at 8.7% CAGR through 2032 due to its critical role in immunomodulatory peptides.

Amino Acids for Peptide Drug Synthesis Market – View in Detailed Research Report

Market Size

The market was valued at USD 414 million in 2024 and is projected to reach USD 727 million by 2032, representing a 9% CAGR.

Product Definition

Amino acids for peptide drug synthesis are high-purity, chemically modified building blocks used in the manufacturing of therapeutic peptides. They include natural and non-proteinogenic variants, protected derivatives, and specialty formulations designed for specific synthesis methods such as SPPS and continuous flow.

🔟 1. Bachem Holding AG

Headquarters: Balgach, Switzerland
Key Offering: GMP‑grade lysine, methionine, threonine, and custom amino acid solutions for peptide synthesis

Bachem is a global leader in peptide synthesis, offering a vertically integrated production chain from raw material to finished API. Their extensive portfolio includes high‑purity amino acids tailored for SPPS, microwave‑assisted synthesis, and emerging continuous flow platforms.

Sustainability & Growth Initiatives:

• Expansion of a 250‑t/yr lysine production line to meet rising demand in oncology and metabolic peptide drugs.
• Investment in green chemistry for solvent‑free amino acid synthesis, reducing CO₂ footprint by 20%.
• Partnerships with major CDMOs to provide on‑demand, just‑in‑time amino acid supplies.

---

9️⃣ 2. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: Custom amino acid solutions, proprietary SAFC derivatives, and GMP‑grade specialty building blocks

Merck’s acquisition of SAFC Commercial in 2019 strengthened its peptide synthesis capabilities, enabling rapid development of non‑proteinogenic amino acids for advanced therapeutics.

Sustainability & Growth Initiatives:

• Launch of a dedicated research unit focused on bio‑based amino acid synthesis.
• Implementation of a closed‑loop solvent recovery system across all amino acid manufacturing sites.
• Strategic collaborations with academic institutions to develop next‑generation peptide conjugates.

---

8️⃣ 3. Kyowa Kirin Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: Fermentation‑derived lysine, methionine, and custom protected amino acids for peptide therapeutics

Kyowa Kirin’s proprietary fermentation technologies provide cost‑efficient, high‑purity amino acids, supporting both domestic and global peptide drug development.

Sustainability & Growth Initiatives:

• Investment in renewable energy for fermentation facilities, targeting 30% reduction in energy use.
• Development of a bio‑based tryptophan platform to meet growing demand in metabolic disease therapies.
• Collaboration with global CDMOs to expand market reach in Asia‑Pacific.

---

7️⃣ 4. Evonik Industries AG

Headquarters: Essen, Germany
Key Offering: Specialty amino acids, protected derivatives, and high‑purity building blocks for peptide synthesis

Evonik’s partnership with BCN Peptides exemplifies its commitment to aligning amino acid supply with emerging peptide drug pipelines.

Sustainability & Growth Initiatives:

• Launch of a green chemistry program to produce Fmoc‑protected amino acids with reduced solvent use.
• Expansion of a 120‑t/yr lysine production line with integrated waste‑to‑energy technology.
• Strategic alliances with CDMOs to support long‑chain peptide development.

---

6️⃣ 5. GL Biochem

Headquarters: Shanghai, China
Key Offering: GMP‑grade lysine, methionine, threonine, and specialty amino acids for peptide drug manufacturing

GL Biochem’s rapid expansion in China’s biopharma sector positions it as a key supplier for domestic and regional peptide drug developers.

Sustainability & Growth Initiatives:

• Implementation of a 100% renewable energy supply chain for amino acid production.
• Development of a low‑cost, high‑purity tryptophan platform for metabolic disease applications.
• Partnerships with local universities to foster talent in peptide chemistry.

---

5️⃣ 6. Chengdu Kelong Chemical Co., Ltd.

Headquarters: Chengdu, China
Key Offering: Cost‑effective lysine and methionine solutions for peptide synthesis

Chengdu Kelong Chemical leverages advanced fermentation and downstream processing to deliver high‑quality amino acids at competitive pricing.

Sustainability & Growth Initiatives:

• Adoption of a zero‑waste production model for protected amino acids.
• Investment in water‑recycling infrastructure to reduce water usage by 25%.
• Collaboration with CDMOs to support regional peptide drug development.

---

4️⃣ 7. Meihua Holdings Group Co., Ltd.

Headquarters: Shenzhen, China
Key Offering: Custom amino acid derivatives and GMP‑grade specialty building blocks

Meihua Holdings focuses on rapid scale‑up of specialty amino acids for advanced peptide therapeutics, catering to the growing demand in oncology and metabolic disease sectors.

Sustainability & Growth Initiatives:

• Development of a green solvent system for amino acid purification.
• Expansion of a 200‑t/yr lysine production line with integrated carbon capture.
• Strategic partnership with global CDMOs to enhance supply chain resilience.

---

3️⃣ 8. Xiuzheng Pharmaceutical Group

Headquarters: Shanghai, China
Key Offering: GMP‑grade lysine and methionine for peptide drug manufacturing

Xiuzheng Pharmaceutical provides high‑purity amino acids to support the rapid growth of China’s peptide drug market.

Sustainability & Growth Initiatives:

• Implementation of a closed‑loop water recycling system.
• Adoption of renewable energy sources for manufacturing operations.
• Collaboration with CDMOs to deliver on‑demand amino acid solutions.

---

2️⃣ 9. Chengdu Zyiochemical Technology Co.

Headquarters: Chengdu, China
Key Offering: Specialty protected amino acids for continuous flow peptide synthesis

Chengdu Zyiochemical’s focus on advanced protecting groups supports the next generation of continuous flow peptide production.

Sustainability & Growth Initiatives:

• Development of a green protecting group chemistry platform.
• Investment in automation to reduce production cycle times by 30%.
• Partnerships with CDMOs to expand global market reach.

---

1️⃣ 10. Chengdu Tachem Technology Co.

Headquarters: Chengdu, China
Key Offering: GMP‑grade lysine and methionine for peptide drug synthesis

Chengdu Tachem’s rapid scale‑up of amino acid production supports the growing demand for peptide therapeutics in China and beyond.

Sustainability & Growth Initiatives:

• Implementation of a renewable energy strategy covering 80% of manufacturing power.
• Launch of a low‑cost, high‑purity tryptophan platform for metabolic disease applications.
• Collaboration with CDMOs to provide flexible supply solutions.

---

Download FREE Sample Report: Amino Acids for Peptide Drug Synthesis Market – View in Detailed Research Report

Get Full Report Here: Amino Acids for Peptide Drug Synthesis Market – View in Detailed Research Report

Outlook: The Future of Amino Acids in Peptide Drug Synthesis

The amino acid market for peptide drug synthesis is poised for dynamic growth, driven by the expansion of peptide therapeutics, technological advancements in synthesis methods, and a global shift towards sustainable manufacturing. With a projected 9% CAGR, the market is expected to reach USD 727 million by 2032, reflecting the increasing demand for high‑purity, specialty amino acids across oncology, metabolic disease, and advanced peptide conjugate segments.

Key Trends Shaping the Market

• Rapid adoption of continuous flow and microwave‑assisted peptide synthesis, reducing amino acid waste by 15‑20%.
• Growth of specialty amino acids for stapled peptides and peptide‑conjugate drugs, with projected CAGR of 18‑20%.
• Increasing focus on green chemistry, including solvent‑free processes and renewable energy utilization.
• Expansion of regional manufacturing hubs in Asia‑Pacific, driven by cost‑effective production and favorable tax incentives.
• Regulatory alignment across major markets (USP, EP, JP) to streamline compliance and reduce time‑to‑market.

Future Outlook (2025‑2034)

Base year 2025: USD 440 million
Estimated 2026: USD 480 million
Forecast 2034: USD 800 million

Frequently Asked Questions

What is the current market size of Global Amino Acids for Peptide Drug Synthesis Market?

-> Global amino acids for peptide drug synthesis market was valued at USD 414 million in 2024 and is projected to reach USD 727 million by 2032, growing at a CAGR of 9.0% during the forecast period.

Which key companies operate in Global Amino Acids for Peptide Drug Synthesis Market?

-> Key players include Bachem, Kyowa Kirin, Merck, Evonik, GL Biochem, Chengdu Kelong Chemical, Meihua Holdings, Xiuzheng Pharmaceutical, Chengdu Zyiochemical Technology, and Chengdu Tachem.

What are the key growth drivers?

-> Key growth drivers include rising demand for peptide-based therapeutics, advancements in synthetic peptide technology, and increasing prevalence of chronic diseases requiring targeted therapies.

Which region dominates the market?

-> North America currently leads the market, while Asia‑Pacific is expected to show the highest growth rate due to expanding pharmaceutical manufacturing capabilities.

What are the emerging trends?

-> Emerging trends include development of novel amino acid derivatives, automation in peptide synthesis, and increasing focus on green chemistry approaches.